


**Figure 1 CONSORT flow diagram of patient disposition**



**Table 1 Demographic information recorded at baseline**

<b>Characteristic</b>	<b>Niraparib (n=57)</b>	<b>ASC (n=31)</b>	<b>Total (n=88)</b>
<b>Age (years)<sup>2</sup></b>			
Median	71	74	72
IQR	63 to 75	66 to 77	65 to 76
Range	33 to 84	51 to 81	33 to 84
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Sex – n(%)<sup>2</sup></b>			
Male	40 (70.2%)	22 (71.0%)	62 (70.5%)
Female	17 (29.8%)	9 (29.0%)	26 (29.5%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Ethnicity – n(%)<sup>2</sup></b>			
White	55 (96.5%)	31 (100%)	86 (97.7%)
Mixed / Multiple ethnic groups	0 (0.0%)	0 (0.0%)	0 (0.0%)
Asian / Asian British	1 (1.8%)	0 (0.0%)	1 (1.1%)
Black / African / Caribbean / Black British	0 (0.0%)	0 (0.0%)	0 (0.0%)
Arab	0 (0.0%)	0 (0.0%)	0 (0.0%)
Not given	1 (1.8%)	0 (0.0%)	1 (1.1%)
Unknown	0 (0.0%)	0 (0.0%)	0 (0.0%)
Any other ethnic group	0 (0.0%)	0 (0.0%)	0 (0.0%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>ECOG – n(%)<sup>2</sup></b>			
0	15 (26.3%)	8 (25.8%)	23 (26.1%)
1	42(73.7%)	23 (74.2%)	65 (73.9%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Asbestos Exposure – n(%)<sup>2</sup></b>			
Yes	30 (52.6%)	10 (32.3%)	40 (45.5%)
No	27 (47.4%)	21 (67.7%)	48 (54.5%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Smoking Status – n(%)<sup>2</sup></b>			
Current Smoker	2 (3.5%)	1 (3.2%)	3 (3.4%)
Non-Smoker	32 (56.1%)	20 (64.5%)	52 (59.1%)
Ex-Smoker	23 (40.4%)	10 (32.3%)	33 (37.5%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Time since diagnosis of mesothelioma (months)<sup>2</sup></b>			
Median	27.6	26.0	26.8
IQR	18.0 to 49.2	18.8 to 43.5	18.7 to 48.9
Range	3.3 to 188.4	9.3 to 124.3	3.3 to 188.4
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Mesothelioma cell type – n(%)<sup>2</sup></b>			

<b>Characteristic</b>	<b>Niraparib (n=57)</b>	<b>ASC (n=31)</b>	<b>Total (n=88)</b>
Epithelioid	50 (87.7%)	27 (87.1%)	77 (87.5%)
Non-epithelioid	7 (12.3%)	4 (12.9%)	11 (12.5%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Site of mesothelioma – n(%)<sup>2</sup></b>			
Pleural	49 (86.0%)	28 (90.3%)	77 (87.5%)
Non-pleural	6 (10.5%)	2 (6.5%)	8 (9.1%)
Other	2 (3.5%)	1 (3.2%)	3 (3.4%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Response to prior platinum based chemotherapy – n(%)<sup>2</sup></b>			
<6 months	16 (28.1%)	8 (25.8%)	24 (27.3%)
≥6 months	41 (71.9%)	23 (74.2%)	64 (72.7%)
Missing from eCRF – n(%) <sup>3</sup>	0 (0.0%)	0 (0.0%)	0 (0.0%)

<sup>1</sup> The numbers in this table relate to those with a Subject Characteristics, Performance Status or Disease Characteristics eCRF available.

<sup>2</sup> These statistics or percentages are calculated using the number of patients with non-missing information.

<sup>3</sup> This percentage is calculated as the number of patients with this information missing divided by those with an eCRF available.

**Table 2 Progression-free survival information, including Cox models**

<b>Characteristic</b>	<b>Niraparib (n=57)</b>	<b>ASC (n=31)</b>	<b>Total (n=88)</b>
<b>Number of events observed – n(%)</b>	55 (96.5%)	28 (90.3%)	83 (94.3%)
<b>Median progression-free survival – median (95% CI)</b>	4.14 (2.76 to 4.73)	2.76 (1.41 to 3.02)	2.96 (2.76 to 4.14)
<b>6-month progression-free survival – % (95% CI)</b>	24.6% (14.4% to 36.2%)	13.8% (4.4% to 28.6%)	20.9% (13.9% to 30.0%)
<b>Cox’s proportional hazards model<sup>1</sup> – unadjusted</b>			
P-value (one-sided)		0.091	
Hazard Ratio		0.731	
One-sided 90% upper confidence limit		0.988	
Two-sided 95% confidence interval		(0.461 to 1.159)	
<b>Cox’s proportional hazards model<sup>1,2</sup> – adjusted</b>			
P-value (one-sided)		0.083	
Hazard Ratio		0.721	
One-sided 90% upper confidence limit		0.975	
Two-sided 95% confidence interval		(0.454 to 1.145)	

<sup>1</sup>Reference category=ASC:

- A HR<1 favours Niraparib
- A HR=1 indicates neither favoured.
- A HR>1 favours ASC

<sup>2</sup>Adjusting for epithelioid vs. non-epithelioid and response to prior platinum-based chemotherapy (<6 months vs ≥6 months).

\*Please note, those patients alive with no reported progression at the time of the study ending will be censored at the time last seen.

Progression-free survival is deemed significant if the one-sided p-value is ≤0.1.

**Table 3 Summary of terms of adverse event**

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Summary of AEs<sup>1,2</sup></b>				
<b>Blood and lymphatic system disorders</b>	<b>9 (15.8%)</b>	<b>3 (9.7%)</b>	<b>4 (7.0%)</b>	<b>1 (3.2%)</b>
Anaemia	9 (15.8%)	3 (9.7%)	2 (3.5%)	1 (3.2%)
Neutropenia	0 (0.0%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
Thrombocytopenia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Cardiac disorders</b>	<b>4 (7.0%)</b>	<b>0 (0.0%)</b>	<b>4 (7.0%)</b>	<b>0 (0.0%)</b>
Atrioventricular block complete	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Cardiac failure	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Cardiomyopathy	1 (1.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Myocardial infraction	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Palpitations	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tachycardia	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Ear and labyrinth disorders</b>	<b>5 (8.8%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Eustachian tube obstruction	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Motion sickness	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tinnitus	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Vertigo	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Endocrine disorders</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Hypophysitis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypothyroidism	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Eye disorders</b>	<b>6 (10.5%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Conjunctival pallor	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dry eye	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Retinal vein occlusion	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Swelling of eyelid	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Visual impairment	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Gastrointestinal disorders</b>	<b>50 (87.7%)</b>	<b>10 (32.3%)</b>	<b>6 (10.5%)</b>	<b>1 (3.2%)</b>
Abdominal distension	3 (5.3%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Abdominal hernia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Abdominal mass	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Abdominal pain	10 (17.5%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
Abdominal pain lower	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Abdominal pain upper	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Anal incontinence	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Anal sphincter hypertonia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Ascites	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Constipation	26 (45.6%)	5 (16.1%)	0 (0.0%)	0 (0.0%)
Diarrhoea	9 (15.8%)	1 (3.2%)	1 (1.8%)	0 (0.0%)
Dry mouth	4 (7.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dyspepsia	5 (8.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Dysphagia	5 (8.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Eructation	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Femoral hernia strangulated	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Gastritis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Gastroesophageal reflux disease	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gingival bleeding	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gingival pain	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mouth ulceration	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nausea	25 (43.9%)	3 (9.7%)	4 (7.0%)	0 (0.0%)
Oral disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)
Periodontal disease	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Post-tussive vomiting	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Retching	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Stomatitis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Toothache	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Umbilical hernia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Vomiting	11 (19.3%)	1 (3.2%)	1 (1.8%)	0 (0.0%)
<b>General disorders and administration site conditions</b>	<b>40 (70.2%)</b>	<b>15 (48.4%)</b>	<b>10 (17.5%)</b>	<b>5 (16.1%)</b>
Axillary pain	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Catheter site pain	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Chest discomfort	0 (0.0%)	2 (6.5%)	0 (0.0%)	0 (0.0%)
Chest pain	11 (19.3%)	4 (12.9%)	0 (0.0%)	0 (0.0%)
Crepitations	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Death	0 (0.0%)	0 (0.0%)	5 (8.8%)	4 (12.9%)
Fatigue	30 (52.6%)	6 (19.4%)	3 (5.3%)	1 (3.2%)
Mucosal inflammation	4 (7.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Non-cardiac chest pain	1 (1.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Oedema peripheral	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pain	5 (8.8%)	4 (12.9%)	0 (0.0%)	0 (0.0%)
Peripheral swelling	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pyrexia	2 (3.5%)	1 (3.2%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Hepatobiliary disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Hepatitis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Immune system disorders</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Contrast media reaction	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Infections and infestations</b>	<b>18 (31.6%)</b>	<b>7 (22.6%)</b>	<b>11 (19.3%)</b>	<b>0 (0.0%)</b>
COVID-19	4 (7.0%)	1 (3.2%)	1 (1.8%)	0 (0.0%)
Catheter site infection	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Clostridium difficile colitis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Herpes zoster	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Infection	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Lower respiratory tract infection	3 (5.3%)	4 (12.9%)	2 (3.5%)	0 (0.0%)
Nasopharyngitis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Oral candidiasis	4 (7.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Peritonitis bacterial	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Pneumonia	1 (1.8%)	0 (0.0%)	3 (5.3%)	0 (0.0%)
Pneumonia bacterial	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Respiratory tract infection	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Sepsis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Tooth abscess	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tooth infection	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinary tract infection	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Wound infection	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Injury, poisoning and procedural complications</b>	<b>4 (7.0%)</b>	<b>1 (3.2%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Back injury	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Contusion	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Drain site complication	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Fall	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Incisional hernia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Procedural pain	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin laceration	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Investigations</b>	<b>19 (33.3%)</b>	<b>4 (12.9%)</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>
Alanine aminotransferase increased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood alkaline phosphatase increased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood bilirubin increased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood cholesterol increased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood creatinine increased	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood magnesium decreased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Blood urea increased	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Blood urine present	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Breath sounds abnormal	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Breath sounds absent	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Haemoglobin decreased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neutrophil count decreased	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Oxygen saturation decreased	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Platelet count decreased	2 (3.5%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
SARS-CoV-2 test positive	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Weight decreased	10 (17.5%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Metabolism and nutrition disorders</b>	<b>23 (40.4%)</b>	<b>10 (32.3%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Decreased appetite	19 (33.3%)	10 (32.3%)	0 (0.0%)	0 (0.0%)
Dehydration	2 (3.5%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Hypercalcaemia	4 (7.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyperglycaemia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypoalbuminaemia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Hypoglycaemia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypokalaemia	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyponatraemia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Hypophagia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Iron deficiency	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Musculoskeletal and connective tissue disorders</b>	<b>23 (40.4%)</b>	<b>9 (29.0%)</b>	<b>3 (5.3%)</b>	<b>0 (0.0%)</b>
Arthralgia	6 (10.5%)	5 (16.1%)	0 (0.0%)	0 (0.0%)
Back pain	8 (14.0%)	3 (9.7%)	0 (0.0%)	0 (0.0%)
Bone pain	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Flank pain	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gouty arthritis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Groin pain	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Joint stiffness	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Joint swelling	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mobility decreased	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Muscle spasms	4 (7.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Muscle weakness	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Musculoskeletal chest pain	3 (5.3%)	2 (6.5%)	1 (1.8%)	0 (0.0%)
Musculoskeletal discomfort	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Myalgia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Myopathy	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pain in extremity	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Pain in jaw	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>1 (1.8%)</b>	<b>1 (3.2%)</b>	<b>4 (7.0%)</b>	<b>1 (3.2%)</b>
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Leukaemia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Malignant neoplasm progression	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Mesothelioma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)
Mesothelioma malignant	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Metastasis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Seborrhoeic keratosis	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Nervous system disorders</b>	<b>25 (43.9%)</b>	<b>6 (19.4%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Balance disorder	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Cerebrovascular accident	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Dizziness	3 (5.3%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Dysarthria	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dysgeusia	5 (8.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Facial paralysis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Headache	7 (12.3%)	2 (6.5%)	0 (0.0%)	0 (0.0%)
Hypoaesthesia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Lethargy	1 (1.8%)	3 (9.7%)	0 (0.0%)	0 (0.0%)
Migraine	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neuralgia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neuropathy peripheral	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Paraesthesia	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Peripheral motor neuropathy	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Presyncope	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Syncope	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Tardive dyskinesia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Taste disorder	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Tremor	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Psychiatric disorders</b>	<b>13 (22.8%)</b>	<b>4 (12.9%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Anxiety	2 (3.5%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Confusion state	1 (1.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Delirium	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Depressed mood	2 (3.5%)	2 (6.5%)	0 (0.0%)	0 (0.0%)
Depression	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hallucination	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Insomnia	6 (10.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mood altered	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sleep disorder	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Renal and urinary disorders</b>	<b>6 (10.5%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Haematuria	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Micturition disorder	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Nocturia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pollakiuria	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Proteinuria	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Renal impairment	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinary incontinence	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Urinary retention	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Reproductive system and breast disorders</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Erectile dysfunction	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Respiratory, thoracic and mediastinal disorders</b>	<b>28 (49.1%)</b>	<b>12 (38.7%)</b>	<b>6 (10.5%)</b>	<b>3 (9.7%)</b>
Cough	9 (15.8%)	5 (16.1%)	0 (0.0%)	0 (0.0%)
Dysphonia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dyspnoea	18 (31.6%)	8 (25.8%)	5 (8.8%)	2 (6.5%)
Dyspnoea exertional	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Epistaxis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hiccups	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Painful respiration	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Pleural effusion	0 (0.0%)	1 (3.2%)	1 (1.8%)	1 (3.2%)
Pleuritic pain	1 (1.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Productive cough	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pulmonary embolism	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Respiratory failure	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Rhinorrhoea	4 (7.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sputum retention	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Wheezing	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Skin and subcutaneous tissue disorders</b>	<b>17 (29.8%)</b>	<b>2 (6.5%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Dry skin	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Erythema	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hyperhidrosis	1 (1.8%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Hyperkeratosis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Night sweats	3 (5.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Petechiae	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Pruritus	4 (7.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rash	5 (8.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Rash erythematous	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
Rash maculo-papular	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Rash papular	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin atrophy	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Skin hypertrophy	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
<b>Surgical and medical procedures</b>	<b>0 (0.0%)</b>	<b>1 (3.2%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>
Gastritis prophylaxis	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
<b>Vascular disorders</b>	<b>12 (21.1%)</b>	<b>5 (16.1%)</b>	<b>3 (5.3%)</b>	<b>1 (3.2%)</b>
Deep vein thrombosis	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)
Essential hypertension	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)
Hot flush	2 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Hypertension	8 (14.0%)	1 (3.2%)	2 (3.5%)	0 (0.0%)
Hypotension	1 (1.8%)	2 (6.5%)	0 (0.0%)	0 (0.0%)
Orthostatic hypotension	0 (0.0%)	1 (3.2%)	1 (1.8%)	0 (0.0%)

<sup>1</sup> Denominator is the number of patients randomised.

<sup>2</sup> A single count is used when more than AE is available per patient per main symptom/SOC term.

**Table 4 Summary of main symptom reported on the SAE form**

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Summary of AEs<sup>1,2</sup></b>				
<b>Blood and lymphatic system disorders</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>
Anaemia	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neutropenia	0 (0.0%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
<b>Cardiac disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>4 (7.0%)</b>	<b>0 (0.0%)</b>
Acute myocardial infarction	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Atrioventricular block complete	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Cardiac failure	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Cardiomyopathy	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Gastrointestinal disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>5 (8.8%)</b>	<b>0 (0.0%)</b>
Abdominal Pain	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Abdominal distension	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Dysphagia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Femoral hernia strangulated	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Nausea	0 (0.0%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
Vomiting	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>General disorders and administration site conditions</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>
Fatigue	1 (1.8%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Non Cardiac Chest Pain	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Infections and infestations</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>10 (17.5%)</b>	<b>0 (0.0%)</b>
Bacterial Peritonitis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
COVID-19	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Infection	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Lower respiratory tract infection	0 (0.0%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
Pneumonia	0 (0.0%)	0 (0.0%)	3 (5.3%)	0 (0.0%)
Respiratory tract infection	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Sepsis	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Injury, poisoning and procedural complications</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Drain site complication	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Metabolism and nutrition disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>
Gout	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Hyponatraemia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Musculoskeletal and connective tissue disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>1 (1.8%)</b>	<b>0 (0.0%)</b>
Musculoskeletal chest pain	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>2 (3.5%)</b>	<b>1 (3.2%)</b>
Bladder cancer	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Leukaemia	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Metastases to central nervous system	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Tongue neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (3.2%)

	Grade 1 & 2		Grade 3, 4 & 5	
	Niraparib (n=57)	ASC (n=31)	Niraparib (n=57)	ASC (n=31)
	Number (%)	Number (%)	Number (%)	Number (%)
<b>Respiratory, thoracic and mediastinal disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>4 (7.0%)</b>	<b>0 (0.0%)</b>
Dyspnoea	0 (0.0%)	0 (0.0%)	2 (3.5%)	0 (0.0%)
Pleural effusion	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Respiratory failure	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
<b>Vascular disorders</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>2 (3.5%)</b>	<b>0 (0.0%)</b>
Cerebrovascular accident	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
Orthostatic hypotension	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)

<sup>1</sup> Denominator is the number of patients randomised.

<sup>2</sup> A single count is used when more than SAE is available per patient per main symptom/SOC term.